DeepMind’s AI system has unlocked the 3D structure of more than 350,000 proteins -but what does this mean for therapeutic advancements?
The integration of AI within pharma manufacturing is slowly increasing, to potentially help keep up with demand on a shorter time scale.
NVIDIA has launched its latest supercomputer. Cambridge-1 has the potential to improve all aspects of life science and pharma research.
The synthetic biology industry is expected to jump from $9.5 billion to $30.7 billion in 2021 – we look at the opportunities and challenges.
Fundamental scientific research has been conducted in space for many years, and more recently, pharma hopes to use this for drug development.
Machine learning, a branch of AI, is making a mark in the pharmaceutical industry, contributing to exciting innovations drug discovery.
Research across the life sciences is utilising machine learning approaches to optimise data analysis: predicting diabetes cases for example.
The keynote of Proventa’s MedChem and Biology Strategy Meeting, with Gilead’s Uli Schmitz, focused on the utilisation of AI in drug discovery.
Risk-based monitoring (RBM) is a useful tool in maximising the quality of clinical trials. The application of AI has shown potential in RBM.
The modernisation of clinical trials is an important part of accelerating drug approval. New innovation, such as AI, offer hope.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settings